Richard P. Baum

24.6k total citations · 7 hit papers
353 papers, 13.1k citations indexed

About

Richard P. Baum is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Epidemiology. According to data from OpenAlex, Richard P. Baum has authored 353 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Oncology, 179 papers in Radiology, Nuclear Medicine and Imaging and 176 papers in Epidemiology. Recurrent topics in Richard P. Baum's work include Neuroendocrine Tumor Research Advances (174 papers), Radiopharmaceutical Chemistry and Applications (141 papers) and Lung Cancer Research Studies (120 papers). Richard P. Baum is often cited by papers focused on Neuroendocrine Tumor Research Advances (174 papers), Radiopharmaceutical Chemistry and Applications (141 papers) and Lung Cancer Research Studies (120 papers). Richard P. Baum collaborates with scholars based in Germany, United States and Netherlands. Richard P. Baum's co-authors include Harshad Kulkarni, Vikas Prasad, Aviral Singh, Christiane Schuchardt, G. Hör, Ingo Klette, Frank Rösch, Stefan Adams, Lisa Bodei and Dirk Müeller and has published in prestigious journals such as Journal of Clinical Oncology, Contemporary Sociology A Journal of Reviews and PLoS ONE.

In The Last Decade

Richard P. Baum

336 papers receiving 12.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

2013 563 citations John J. Zaknun, Richard P. Baum et al. profile →
⁶⁸Ga- and ¹⁷⁷Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

2015 419 citations Richard P. Baum, Harshad Kulkarni et al. profile →
Processing of Generator-Produced 68Ga for Medical Application

2007 419 citations Richard P. Baum et al. profile →
¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

2016 397 citations Richard P. Baum, Harshad Kulkarni et al. profile →
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

2014 328 citations Richard P. Baum et al. profile →
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-Dotatate in the Phase III NETTER-1 Trial

2018 272 citations Richard P. Baum et al. profile →
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

2021 210 citations Richard P. Baum, Aviral Singh et al. profile →

Peers

Countries citing papers authored by Richard P. Baum

Since Specialization

Citations

This map shows the geographic impact of Richard P. Baum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard P. Baum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard P. Baum more than expected).

Fields of papers citing papers by Richard P. Baum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard P. Baum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard P. Baum. The network helps show where Richard P. Baum may publish in the future.

Co-authorship network of co-authors of Richard P. Baum

This figure shows the co-authorship network connecting the top 25 collaborators of Richard P. Baum. A scholar is included among the top collaborators of Richard P. Baum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard P. Baum. Richard P. Baum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimizing theranostics chatbots with context-augmented large language models 2025 ·Theranostics ·(unknown), (unknown), (unknown), Robert Seifert, (unknown), George Prenosil, Mike Sathekge, Ken Herrmann, Richard P. Baum, Wolfgang Weber, Axel Rominger, Kuangyu Shi	1
2	Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer 2025 ·Cancers ·(unknown), Alessandro Giordano, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, (unknown), (unknown), (unknown), (unknown), Axel Heidenreich, Ralph M. Wirtz, (unknown), (unknown), Richard P. Baum	2
3	Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival 2025 ·Cancers ·(unknown), Maria Lucia Calcagni, Lucia Leccisotti, (unknown), (unknown), (unknown), (unknown), (unknown), Richard P. Baum	1
4	Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides 2024 ·Seminars in Nuclear Medicine ·Richard P. Baum, Emil Novruzov, Tianzhi Zhao, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jens Cardinale, Yuriko Mori, Frederik L. Giesel, Jingjing Zhang	10
5	Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer 2024 ·Cancers ·Finn Edler von Eyben, Irene Virgolini, Richard P. Baum	1
6	PSMA radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry 2023 ·Nuklearmedizin - NuclearMedicine ·(unknown), Jingjie Zhang, (unknown), Xudong Chen, (unknown), Richard P. Baum	1
7	Einfluss der PSMA-Radioligandentherapie (PRLT) auf die Immunogenität einer Impfung gegen SARS-CoV-2 - eine retrospektive einarmige Kohortenstudie bei Patienten mit metastasierten Prostatakarzinomen 2023 ·Nuklearmedizin - NuclearMedicine ·(unknown), (unknown), (unknown), (unknown), Cristina Müller, (unknown), Richard P. Baum	0
8	Radiolabeling of 3BP-3940 with 68Ga, 90Y, 177Lu and 225Ac for imaging and Peptide Targeted Radiotherapy (PTRT) 2023 ·Nuklearmedizin - NuclearMedicine ·(unknown), Mike W. Martin, (unknown), (unknown), Cristina Müller, (unknown), (unknown), (unknown), (unknown), Frank Rösch, Richard P. Baum	1
9	Fibroblast Activating Protein (FAP)-Targeted Radiopeptide Therapy using 177Lu-, 225Ac- and 90Y-labeled 3BP-3940 in Diverse Advanced Solid Tumors: First-in-Humans Results 2023 ·Nuklearmedizin - NuclearMedicine ·Jian Zhang, (unknown), (unknown), (unknown), (unknown), (unknown), Elçin Zan, (unknown), (unknown), Cristina Müller, (unknown), Richard P. Baum	0
10	Peptide Receptor Radionuclide Therapy in Patients with Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety and Survival Predictors 2023 ·Nuklearmedizin - NuclearMedicine ·(unknown), (unknown), Tianzhi Zhao, (unknown), X. Chen, (unknown), Jian Zhang, Richard P. Baum	3
11	First-in-human Study of an Optimized, Kit-type, SSTR Antagonist 68Ga-DATA5m-LM4 in Patients with Metastatic Neuroendocrine Tumors 2023 ·Nuklearmedizin - NuclearMedicine ·Jian Zhang, (unknown), (unknown), (unknown), Elçin Zan, (unknown), Frank Rösch, (unknown), Cristina Müller, Richard P. Baum	1
12	Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group 2018 ·The Prostate ·Andrea K. Miyahira, Kenneth J. Pienta, Michael J. Morris, Neil H. Bander, Richard P. Baum, Wolfgang P. Fendler, William Goeckeler, Michael A. Gorin, Hartwig Hennekes, Martin G. Pomper, Oliver Sartor, Scott T. Tagawa, Scott Williams, Howard R. Soule	32
13	Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases 2017 ·Neuroendocrinology ·Maxime Ronot, Ashley Kieran Clift, Richard P. Baum, Aviral Singh, Harshad Kulkarni, Andrea Frilling, Valérie Vilgrain	42
14	Theranostics, Gallium-68, and other radionuclides : a pathway to personalized diagnosis and treatment 2013 ·DIAL (Catholic University of Leuven) ·Richard P. Baum, Frank Rösch	4
15	Pancreatic neuroendocrine neoplasms. 2012 ·PubMed ·Dieter Hörsch, Tillmann Bert, J. Schrader, Merten Hommann, Daniel Kaemmerer, Alexander Petrovitch, John J. Zaknun, Richard P. Baum	10
16	FDG-PET, PET/CT und konventionelle nuklearmedizinische Untersuchungen zur Bewertung des Lungenkrebses: Eine systematische Übersicht 2009 ·Nuklearmedizin - NuclearMedicine ·D. Hellwig, Richard P. Baum, Claudia Kirsch	39
17	OVAREX™ MAb-B43.13:IFN-γ Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cells 1997 ·Hybridoma ·Ragupathy Madiyalakan, Rong Yang, Birgit C. Schultes, Richard P. Baum, A.A. Noujaim	10
18	Evaluation of Tumor Immunity in Patients with Ovarian Cancer after Immunoscintigraphy in a Long-Term Follow-up 1995 ·Hybridoma ·(unknown), Richard P. Baum, (unknown), (unknown), (unknown), G. Hör	2
19	Romanistik : eine Bonner Erfindung 1993 ·Bouvier eBooks ·(unknown), Richard P. Baum, (unknown)	0
20	Musik und Verlag : Karl Vötterle zum 65. Geburtstag am 12. April 1968 1968 ·Bärenreiter eBooks ·Richard P. Baum, Wolfgang Rehm	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact